Canada markets closed

Novartis AG (NVSEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
75.70+0.20 (+0.27%)
At close: 02:17PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • B
    MASSIVE order are coming in at the close, huge volume. Large institutions on the move again🤑🚀
  • S
    To be a super trader, you'll need to edge to overcome the laws of probability and uncertainty of the marketplace, that edge comes from information flows, the ability to correct your habits in terms of the matter characteristics, and being able to learn from people who knows more than you, cut losses, expand your information network, ferret out ideas and take recommendations
    Someone who will probably assist you in day trading with daily signals too 👉 Clara Austin on Face🧾book I've accumulated over 11Btc trading and implementing her strategies.
    Log into Facebook to start sharing and connecting with your friends, family, and people you know.
    Log into Facebook to start sharing and connecting with your friends, family, and people you know.
  • P
    Great NVS clinical news today out of Basel. Stock is beaten down and much too low.
  • S
    sounds good news to investors that there selling SANDOZ ( suffering from bad growth since ‘20).
    So at $25bn value, how much cash are NVS going to have after sales in Roche stake and also selling stake in GSK venture?

    has to be over $60-70bn if this sale goes through.

    Could leave them open to making a bid for AMGN or maybe GILD? ?
  • D
    Please have a look at ticker ILUS as well my fellow investors, they are rapidly expanding & uplisting in 2022. ILUS International is a rather new company that has increased profits and revenue every quarter since inception. ILUS Internationals year over year revenue is up 588%. ILUS has also just reported on 8/15/2022, a 553 percent increase in revenue over their previous quarter.
    ILUS has just merged Wikisoft, formerly ticker WSFT, into their new 100 - million dollar in revenue acquisition, Quality International. They are now called Quality Industrial. This ILUS company is now trading under the ticker QIND.
    ILUS is building a conglomerate, with several different companies and divisions under the ILUS umbrella. ILUS manufactures EV's, UAV's, and Drones to name a few of their many business endeavors. They are also involved in Urban Mining, the Metaverse, and the very lucrative firefighting and fire safety technology sector. ILUS holds patented firefighting / safety technology. They are developing technology to assist with the containment of both EV battery, and wildfires. The wildfires out west are a major concern and solutions are being developed. ILUS is looking to save lives. They have had several meaningful discussions with the state of California, among other states as well.
    ILUS is an M & A company and growing fast. ILUS is about to begin manufacturing the E-Raptor, the worlds first and only six-wheel, all electric utility vehicle. This will take place at the new 600,000 plus square foot facility in Serbia. It is a part of a significant deal that ILUS has signed with the European Union. ILUS International will begin manufacturing a variety of vehicles including those used by the military and defense sectors in Europe. ILUS will surely benefit from the major increase in defense spending that is taking place globally. ILUS will be doing a significant amount of business with the private sector as well.
    ILUS will incorporate in their manufacturing processes their own urban mining / battery recycling into their EV lines. ILUS has completed "7" acquisitions in the last 18 months. Vira Drones is one of the more significant. Vira Drones has an estimated billion- dollar valuation. ILUS has increased their 2022 revenue forecast from 40- million to 140- million dollars. They recently announced a 2023 revenue estimate of 1 -billion dollars. In addition, ILUS has several new acquisitions and revenue sources yet to be officially announced. They are all very significant acquisitions as far as the revenue & profits in which they will add to the already strong balance sheet. Please see Yahoo Finance for more details and news.
  • d
    Prob use it to pay a big dividend
  • A
    imagine if we had the P/E of Tesla.
  • P
    Why is NVS trading at an 8 PE? Seems far below peers.
  • t
    Looks like Novartis will owe 9 figures in royalties to RGNX for a very long time with approval of Zolgensma.At 1.7 billion market cap of RGNX with its 450 million in cash and 0 debt, it would be much cheaper to buy RGNX as it also owns a 100 AAV gene library which has a private market value of $6 billion USD
  • C
    Biggest winner is the babies. Then biggest winner is RGNX = Regenex bio which gets 9-13 % royalties on Zolgensma which makes it 9 figures on royalties or $6-7 eps in 24 months. AT RGNX $48 it has $450 million in cach and 0 debt and sells at book value. It owns the $6 billion private market value 100 AAV gene platform which is used by every gene therapy drug to make it work as a gene vector. RGNX worth over $155+ a share and is involved in ALS= Lou Gehrigs disease and Rett syndrome and SMA type 1 and Sma type 2 with Novartis.
  • T
    The stock will climb into the 90's next week. I will add on to my position on Tuesday. Very impressive week for NVS. Deep pipeline makes NVS a stock with a lot price appreciation for years to come.
  • t
    FDA Accepts AveXis’ BLA for SMA Drug Zolgensma Under Priority Review
    MDA STAFF 12/03/2018
    Today, Novartis, the parent company of AveXis Inc., announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) under Priority Review for Zolgensma (formerly known as AVXS-101), a gene therapy for the treatment of spinal muscular atrophy (SMA) type 1. Priority Review status requires the FDA to review the application and make a decision on whether to approve Zolgensma within six months (the typical review period is 10 months). An anticipated decision is expected in May 2019.

    Zolgensma is a gene therapy that targets the root cause of SMA by delivering a gene to replace the missing or mutated survival of the motor neuron 1 (SMN1) gene. The therapy is a one-time infusion. SMA is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement. Infants with SMA type 1 typically do not survive more than two years.

    Treatment with the therapy in a Phase 1 clinical trial was associated with an increased survival rate compared to the normal course of the disease and the achievement and maintenance of motor milestones that infants with SMA type 1 normally would not be expected to achieve. In the START trial, all 15 patients infused with Zolgensma — three with low dose, 12 with high dose — were alive and event-free at 24 months, compared to 8 percent in a natural history study. An “event” was defined as either death, or at least 16 hours per day of required ventilation support for breathing for 14 consecutive days in the absence of acute reversible illness or surgery. At 24 months, 11 of the 12 high-dose patients could keep their head erect for more than three seconds and sit without support for more than five seconds, 10 patients were able to sit without support for more than 10 seconds, 9 patients were able to sit without support for more than 30 seconds and two patients were able to stand and walk alone without assistance.

    The trial also showed meaningful respiratory results. Of the 10 patients who were not using non-invasive ventilation (NIV) at the start of the trial, seven of them remained NIV-free after 24 months. More importantly, all patients, whether ventilated or not, survived respiratory hospitalizations without tracheostomy or permanent ventilation.

    The most commonly observed side effect of Zolgensma was elevated liver enzymes.

    This announcement underscores the importance of newborn screening to diagnose SMA before babies are symptomatic so they can be treated as early as possible. With the news earlier in the year of SMA being added to the national Recommended Uniform Screening Panel (RUSP), this latest announcement makes it even more important for states to add SMA to their respective newborn screening panels to find babies who may benefit from approved therapies or be eligible to participate in clinical trials.

    Zolgensma is currently in Phase 3 clinical trials for SMA type 1 and is also being tested in a Phase 1 trial for SMA type 2. Additionally, Zolgensma is being tested in a Phase 3 trial for pre-symptomatic newborns diagnosed with SMA types 1, 2 and 3.

    For information regarding eligibility criteria for currently enrolling or planned clinical trials, view the listings on or, or contact

    For more information regarding Zolgensma, check back at

    Click here to read the press release from AveXis.
    Home -
  • a
    Calling all Novartis insiders/employees .... any truth to the statement... "Gerons banking info has been added to the NOVARTIS financial system?" thanks for your input.
  • R
    RGNX and NVS reporting on Bloomberg very positive news on Zolgensma Novartis logo: a global healthcare company
    Our Company

    Our Focus

    Our Science

    Join Us
    AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
    May 05, 2019
    Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)

    New interim data from STR1VE in SMA Type 1 continued to show prolonged event-free survival, increases in motor function and significant milestone achievement consistent with Phase 1 START trial

    Interim data reported for the first time from SPR1NT in pre-symptomatic SMA showed age-appropriate motor milestone achievement
    Basel, May 5, 2019 - AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)1 that showed positive results across a broad spectrum of patients with spinal muscular atrophy (SMA). These included the first presentation of data from the Phase 1 STRONG trial, which showed motor function gains and milestone achievements in patients with SMA Type 2 via intrathecal (IT) delivery; new data from the Phase 3 STR1VE trial, which continued to show prolonged event-free survival, increases in motor function and significant milestone achievement consistent with the Phase 1 START trial; and the first presentation of data from the Phase 3 SPR1NT trial, which showed motor milestone achievement consistent with normal development in SMA patients treated pre-symptomatically. These data were presented during the 2019 American Academy of Neurology (AAN) Annual Meeting.

    "With just a single, one-time dose, we are seeing Zolgensma provide prolonged survival, rapid motor function improvement and milestone achievements that patients never experience if their disease is left untreated," said David Lennon, President of AveXis. "These robust data presented at AAN represent a growing body of evidence that support the use of Zolgensma as a potential foundational therapy for the treatment of SMA across a variety of populations."

    Phase 1 STRONG Data as of March 8, 2019
    STRONG is a Phase 1, open-label, dose-comparison, multi-center trial designed to evaluate the safety and tolerability of one-time IT administration of Zolgensma in patients with SMA Type 2 who have three copies of the SMN2 gene, and who are able to sit but cannot stand or walk at the time of study entry. Patients were stratified into two groups based on age at time of dosing: patients who are >=6 months but <24 months, and patients who are >=24 months but <60 months. The primary efficacy outcome for patients who were >=6 to <24 months is the ability to stand without support >=3 seconds; the primary efficacy outcome for patients who were >=24 to >60 months is change in Hammersmith Functional Motor Scale-Expanded (HFMSE) score from baseline. Three dosing strengths are being evaluated. Only 3/34 (8.8 percent) patients were excluded due to elevated AAV9 antibodies.

    Patients in the STRONG study showed improvement in motor function, with 19 patients (12/12 dosed at >=24 to <60 months and 7 who were dosed at >=6 to <24 months who then became old enough to be evaluated on the HSMSE) having a mean 4.2-point increase from baseline in HFMSE as of their most recent study visit (5-12 months post-treatment). Half of the patients (6/12) who were >=24 months at dosing experienced a >=3-point improvement from baseline in HFMSE by one-month post dosing.
    Since dosing, 22 motor milestones in 10 patients have been achieved according to the Bayley-III Gross Motor Milestone Scale across the Dose A and Dose B treatment groups, including two patients who gained the ability to stand independently, one of whom went on to walk alone in the younger group, and one additional patient who gained the ability to walk with assistance in the older group. The median duration of follow-up was 6.5 months. Efficacy data from Dose C are not presented because enrollment is not complete.

    All patients (n=30) were alive. There were two serious treatment-related adverse events. Both were of transaminase elevation. The frequency of patients with adverse events of transaminase elevation appeared to be lower than that seen with intravenous (IV) administration of Zolgensma.

    "With an average of just over six months of data available for these Type 2 patients following treatment with Zolgensma, we are pleased to see they are achieving motor milestones, including the ability to stand and walk," said Olga Santiago, M.D., Chief Medical Officer of AveXis. "Based on these early promising data, we plan to approach regulators to define the path to registration for intrathecal administration of Zolgensma."

    Phase 3 STR1VE Data as of March 8, 2019
    STR1VE is an ongoing, open-label, single-arm, single-dose, multi-c
  • S
    This is why the selloff today: NEW YORK, Aug 6 (Reuters) - The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis’ more than $2 million gene therapy Zolgensma was manipulated, but the agency believes the treatment should remain on the market.

    The FDA said it is carefully assessing the situation. It said the manipulation involves the accuracy of certain data from product testing performed in animals, which was used by the manufacturer to support the development of its production process.
  • c
    Hi. Does anyone have an idea for why ARK Invest is investing in Novartis? I'm assuming it's for the gene therapy division, but I'm not certain.
  • D
    I'm not knoweledgable with novartis.. but who could tell me why ark buys novartis every single day???